title: Treatment of severe, recalcitrant, chronic plaque psoriasis with fumaric acid esters: a prospective study.
abstract: BACKGROUND
  Fumaric acid esters (FAE) are used in Germany as a first-line systemic treatment for chronic plaque psoriasis, with proven efficacy and low toxicity. Their use in the U.K. is variable, and they remain unlicensed. Consequently, efficacy and safety data from U.K. patients is limited and their place in the psoriasis treatment armamentarium is unclear.
  
  
  OBJECTIVE
  To examine the efficacy and safety of FAE in a prospective cohort of U.K. patients with severe, treatment-recalcitrant, chronic plaque psoriasis.
  
  
  METHODS
  A single-centre, open, nonrandomized, prospective study was performed in a regional referral centre for patients with severe psoriasis. Outcomes were measured by the Psoriasis Area and Severity Index (PASI), Dermatology Life Quality Index (DLQI), blood investigations and adverse events monitoring.
  
  
  RESULTS
  Eighty patients were recruited. Fifty-nine per cent were taking a concomitant oral antipsoriatic agent; 20% achieved a PASI-50, 8% a PASI-75 and 4% a PASI-90 on intention-to-treat analysis at 3 months with an overall, statistically significant, reduction in PASI from 13.9 + or - 9.0 to 11.3 + or - 9.2 (P < 0.0001). At 3 months, lymphopenia was seen in 33% of the cohort with significantly lower counts in patients responsive to FAE (P = 0.008). In addition, by 3 months, 36% of concomitant antipsoriatic medication had been stopped and 25% of doses had been reduced without loss of disease control. Side-effects (most commonly diarrhoea, abdominal pain and flushing) were reported by 74% of patients resulting in cessation of FAE in 36%.
  
  
  CONCLUSIONS
  FAE is a useful alternative treatment option in patients with severe, treatment-resistant, chronic plaque psoriasis and can allow dose reduction, and subsequent cessation, of other, potentially more toxic agents.
authors.affiliation: Skin Therapy Research Unit, St John's Institute of Dermatology, Division of Genetics and Molecular Medicine, King's College, St Thomas' Hospital, London SE1 7EH, London.
authors.forename: E M
authors.initials: EM
authors.lastname: Wain
authors.forename: M I
authors.initials: MI
authors.lastname: Darling
authors.forename: R D
authors.initials: RD
authors.lastname: Pleass
authors.forename: J N W N
authors.initials: JN
authors.lastname: Barker
authors.forename: C H
authors.initials: CH
authors.lastname: Smith
mesh_terms: D000328:Adult; D000368:Aged; D002908:Chronic Disease; D015331:Cohort Studies; D003879:Dermatologic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000069462:Dimethyl Fumarate; D005260:Female; D005650:Fumarates / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011565:Psoriasis / Q000188:drug therapy*; D012720:Severity of Illness Index; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D003879:Dermatologic Agents; D005650:Fumarates; D000069462:Dimethyl Fumarate